Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rodin Therapeutics Inc.

Epigenetic agents for treating cognitive disorders

This article was originally published in Start Up

Executive Summary

Epigenetics continues to be a hot experimental field, but few drugs for modifying gene transcription to control cell-cycle progression have been tried out for central nervous system disorders despite scientific evidence linking aberrant epigenetic processes to several neurodegenerative conditions. Rodin Therapeutics Inc. is stepping in by bringing together international expertise in structural biology with CNS drug development leadership to discover and develop epigenetic agents for Alzheimer’s disease and other CNS disorders.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts